ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics announces that research related to its PrecivityAD™ blood test will soon be presented at upcoming international conferences. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.
Recently, the Journal of the American Medical Association Neurology published findings from BioFINDER’s large comparison of blood plasma amyloid-beta assays. One of the types of assays included in the study was the liquid chromatography–mass spectrometry (LC-MS/MS) assay that Dr. Randall Bateman and his laboratory developed at Washington University that underpins the PrecivityAD™ blood test. The international research group found it performed the best out of seven assays for predicting brain amyloid presence, including in the measurement of phosphorylated tau-217, another Alzheimer’s biomarker.
The following are details about the new presentations:
Tuesday, Nov. 9
5:05 p.m. EST: Recent advances in plasma biomarkers to improve preclinical and prodromal AD trials
Dr. Randy Bateman, Washington University School of Medicine and a C2N scientific co-founder, will present blood plasma measures of amyloid beta (Aβ), tau, and neurofilament light species for screening and use in clinical trials of Alzheimer’s disease.
Wed., Nov. 10
3:45 p.m. EST: ROC9 - Performance of the PrecivityAD™ blood test in detection of brain amyloidosis in cognitively normal and cognitively impaired individuals
Dr. Suzanne Schindler, Washington University School of Medicine, will present performance of the PrecivityAD™ blood test in detection of brain amyloidosis in cognitively normal and cognitively impaired individuals.
Nov. 10 – 13, online
Drs. Mark Monane, Jonathan Drake and B. Joy Snider will present “Early Clinical Utility Data of a Blood Biomarker Test in the Evaluation of Mild Cognitive Impairment” in a poster session. The program objective was to evaluate the clinical utility of the PrecivityAD™ blood test and the Amyloid Probability Score (APS), the test output value. Four academic medical centers were included in this evaluation.
These developments follow researchers’ round-robin findings that determined Aβ in a patient’s blood can be a pre-screen or a substitute for costly PET scans or invasive cerebrospinal fluid (also known as spinal tap) screenings that clinicians use to aid in diagnosing Alzheimer’s disease. The researchers examined the performance of six plasma Aβ assays in their ability to identify Aβ as determined by PET scans; they found that the LC-MS/MS assay that Dr. Bateman developed performed best in its ability to identify amyloid plaque.
About C2N Diagnostics, LLC
C2N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C2N strives to provide exceptional laboratory services and products in the field of brain health. C2N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit: www.C2N.com.